Mizuho lowered the firm’s price target on Quest Diagnostics to $150 from $165 and keeps a Buy rating on the shares. The analyst reduced estimates following the company’s Q4 results and initial 2024 guidance, which came in below expectations mainly due to higher interest costs. While operating margins were a disappointment, 2024 is a reset year for Quest as the company should return to long-term growth rates in 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Announces 5.6% Quarterly Dividend Hike
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Notable companies reporting before tomorrow’s open
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quest Diagnostics price target lowered to $152 from $153 at JPMorgan
